{"id":"lamivudine-oral-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Pancreatitis"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Lactic acidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lamivudine is a cytidine analog that gets phosphorylated intracellularly and incorporated into the growing DNA chain during reverse transcription, causing chain termination. By inhibiting reverse transcriptase, it prevents HIV from converting its RNA genome into DNA that can integrate into the host cell genome. It also has activity against hepatitis B virus through similar mechanisms.","oneSentence":"Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV reverse transcriptase, preventing viral replication by inhibiting the conversion of viral RNA to DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:51:35.753Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (in combination antiretroviral therapy)"},{"name":"Chronic hepatitis B infection"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT04704024","phase":"PHASE3","title":"Reducing Vertical Transmission of Hepatitis B in Africa","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-09-03","conditions":"Hepatitis B Infection","enrollment":450},{"nctId":"NCT02363452","phase":"PHASE2","title":"Reverse Transcriptase Inhibitors in AGS","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-09-10","conditions":"Aicardi-Goutières Syndrome (AGS)","enrollment":11},{"nctId":"NCT04731103","phase":"PHASE2","title":"Inhibition of Reverse Transcription in Aicardi-Goutières Syndrome","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2022-08-24","conditions":"Aicardi-Goutières Syndrome","enrollment":13},{"nctId":"NCT03870438","phase":"PHASE3","title":"Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2019-12-14","conditions":"HIV-1","enrollment":1506},{"nctId":"NCT03869944","phase":"PHASE2","title":"Preventing Childhood HIV: Rescue Intervention. ANRS 12388 PREVENIR-PEV","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2019-12-04","conditions":"HIV-1","enrollment":97},{"nctId":"NCT00672412","phase":"PHASE1, PHASE2","title":"Safety and Pharmacokinetic Study of Fixed Dose Combination of Zidovudine, Lamivudine, and Nevirapine in HIV-Infected Children in Thailand","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-10","conditions":"HIV Infections","enrollment":42},{"nctId":"NCT01818258","phase":"PHASE4","title":"IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2015-10-26","conditions":"HIV Positive, Malnourished","enrollment":52},{"nctId":"NCT02263079","phase":"PHASE3","title":"A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-06-16","conditions":"Pediatric Immuno-Tolerant Chronic Hepatitis B","enrollment":62},{"nctId":"NCT02246998","phase":"PHASE4","title":"Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-12-15","conditions":"HIV-1 Infection","enrollment":72},{"nctId":"NCT02634073","phase":"PHASE4","title":"A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-01-01","conditions":"Infection, Human Immunodeficiency Virus","enrollment":16},{"nctId":"NCT00640263","phase":"PHASE3","title":"Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2009-12","conditions":"HIV Infections","enrollment":1500}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"DEATH"}],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["3TC"],"phase":"marketed","status":"active","brandName":"Lamivudine Oral Solution","genericName":"Lamivudine Oral Solution","companyName":"ANRS, Emerging Infectious Diseases","companyId":"anrs-emerging-infectious-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV reverse transcriptase, preventing viral replication by inhibiting the conversion of viral RNA to DNA. Used for HIV-1 infection (in combination antiretroviral therapy), Chronic hepatitis B infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}